Market Overview

HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold

HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold

Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright.

The Analyst

H.C. Wainwright & Co's Joseph Pantginis initiated coverage of Palatin Technologies' stock with a Buy rating and $5 price target.

The Thesis

Bremelanotide, a treatment for hypoactive sexual desire disorder in women, offers investors a "derisked opportunity" for three reasons, Pantginis said in the initiation note. They are:

  • A New Drug Application was already filed with the FDA on March 26.
  • Two Phase 3 studies yielded positive results.
  • A North American partnership is already in place with AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG).
  • Regional partnerships in China and Korea are already established.

Four more potential catalysts are not presently reflected in Palatin's share price, Pantginis said: 

  • Expectations for a partnership in Europe.
  • The potential to become the first company to have a first-in-class and best-in-class drug for an unaddressed market.
  • Expectations for full FDA approval.
  • A management team with proven execution.

Price Action

Shares of Palatin Technologies were trading higher by 3.33 percent at the time of publication Friday. 

Related Links:

Benzinga Pro's 5 Stocks To Watch Today

Benzinga's Top Upgrades, Downgrades For April 6, 2018

Latest Ratings for PTN

Jun 2018Initiates Coverage OnBuy
Apr 2018Initiates Coverage OnBuy
Jun 2015MaintainsBuy

View More Analyst Ratings for PTN
View the Latest Analyst Ratings

Posted-In: Biopharmaceutical bremelanotideAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (PTN + AMAG)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Argus Expects Solid Returns From Insurer Chubb, But Says Shares Are Fairly Valued

Benzinga's Top Analyst Calls From April 6, 2018